PE20191557A1 - Compuestos de pirimidinil-pyridiloxi-naftil y metodos para tratar enfermedades y trastornos relacionados con ire1 - Google Patents

Compuestos de pirimidinil-pyridiloxi-naftil y metodos para tratar enfermedades y trastornos relacionados con ire1

Info

Publication number
PE20191557A1
PE20191557A1 PE2019001893A PE2019001893A PE20191557A1 PE 20191557 A1 PE20191557 A1 PE 20191557A1 PE 2019001893 A PE2019001893 A PE 2019001893A PE 2019001893 A PE2019001893 A PE 2019001893A PE 20191557 A1 PE20191557 A1 PE 20191557A1
Authority
PE
Peru
Prior art keywords
compounds
naftile
pyridyloxy
disorders1
pirimidinyl
Prior art date
Application number
PE2019001893A
Other languages
English (en)
Inventor
Marie-Gabrielle Braun
Paul Gibbons
Wendy Lee
Cuong Ly
Joachim Rudolph
Jacob Schwarz
Avi Ashkenazi
Leo Fu
Tommy Lai
Fei Wang
Ramsay Beveridge
Liang Zhao
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of PE20191557A1 publication Critical patent/PE20191557A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

REFERIDO A COMPUESTOS PIRIMIDINIL-PIRIDILOXI-NAFTIL DE FORMULA (I') DONDE R1, R2, R3, R4, R5, R6, R7 Y n SON TAL COMO SE DEFINEN EN LA DESCRIPCION. SON COMPUESTOS PREFERIDOS: (S)-3-(2-CIANOPROPAN-2-IL)-N-(6-METIL-5-((3-(2-(PIPERIDIN-3-ILAMINO)PIRIMIDIN-4-IL)PIRIDIN-2-IL)OXI)NAFTALEN-1-IL)BENZAMIDA; (S)-1-(2-CLOROFENIL)-N-(2-FLUORO-6-METIL-5-((3-(2-(PIPERIDIN-3-ILAMINO)PIRIMIDIN-4-IL)PIRIDIN-2-IL)OXI)NAFTALEN-1-IL)METANOSULFONAMIDA; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS TIENEN ACTIVIDAD DE MODULACION DE LA ENZIMA REQUIRENTE DE INOSITOL 1 (IRE1) SIENDO UTILES EN EL TRATAMIENTO DE CANCER MICROCITICO DE PULMON, ADENOCARCINOMA DE PULMON
PE2019001893A 2017-03-17 2018-03-16 Compuestos de pirimidinil-pyridiloxi-naftil y metodos para tratar enfermedades y trastornos relacionados con ire1 PE20191557A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2017077059 2017-03-17
PCT/CN2018/079292 WO2018166528A1 (en) 2017-03-17 2018-03-16 Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating ire1-related diseases and disorders

Publications (1)

Publication Number Publication Date
PE20191557A1 true PE20191557A1 (es) 2019-10-24

Family

ID=63522807

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2019001893A PE20191557A1 (es) 2017-03-17 2018-03-16 Compuestos de pirimidinil-pyridiloxi-naftil y metodos para tratar enfermedades y trastornos relacionados con ire1

Country Status (17)

Country Link
US (1) US10968203B2 (es)
EP (1) EP3596063A4 (es)
JP (1) JP6925435B2 (es)
KR (1) KR20190141145A (es)
CN (1) CN111247136A (es)
AR (1) AR111281A1 (es)
AU (1) AU2018233402A1 (es)
BR (1) BR112019019193A2 (es)
CA (1) CA3056833A1 (es)
CL (1) CL2019002671A1 (es)
CO (1) CO2019010078A2 (es)
CR (1) CR20190433A (es)
IL (1) IL269302A (es)
PE (1) PE20191557A1 (es)
SG (1) SG11201908517XA (es)
TW (1) TW201838981A (es)
WO (1) WO2018166528A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180346446A1 (en) 2017-06-01 2018-12-06 Quentis Therapeutics, Inc. Ire1 small molecule inhibitors
US10392367B2 (en) 2017-06-01 2019-08-27 Quentis Therapeutics, Inc. IRE1 small molecule inhibitors
WO2020047518A1 (en) * 2018-08-30 2020-03-05 The Regents Of The University Of California Ire1 kinase inhibitors and uses thereof
JP7098826B2 (ja) * 2018-09-12 2022-07-11 ジェネンテック， インコーポレイテッド ピリミジニル－ヘテロアリールオキシ－ナフチル化合物および使用方法
US11945784B2 (en) 2018-12-03 2024-04-02 Cornell University IRE1 small molecule inhibitors
EP3891137A1 (en) * 2018-12-03 2021-10-13 Cornell University Ire1 small molecule inhibitors
US20220227730A1 (en) * 2019-05-15 2022-07-21 Cornell University Treatment of fibrosis with ire1 small molecule inhibitors
US20230331719A1 (en) * 2020-08-07 2023-10-19 Optikira, LLC Pyrazolopyridine Compounds and Methods of Inhibiting IRE1 Using Same
US11884649B2 (en) 2020-11-13 2024-01-30 The Regents Of The University Of California IRE1α inhibitors and uses thereof
CN116710429A (zh) * 2020-11-13 2023-09-05 加利福尼亚大学董事会 IRE1α抑制剂及其用途
CN114907350B (zh) * 2021-02-10 2023-12-29 上海凌达生物医药有限公司 一类含氮稠环类化合物、制备方法和用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005113494A2 (en) * 2004-05-07 2005-12-01 Amgen Inc. Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer
US7868177B2 (en) 2006-02-24 2011-01-11 Amgen Inc. Multi-cyclic compounds and method of use
AU2009290617B2 (en) 2008-09-15 2015-05-14 Fundacion Ciencia Para La Vida Methods and compositions for modulating Ire1, Src, and Abl activity
US9688662B2 (en) 2013-04-04 2017-06-27 Janssen Pharmaceutica Nv N-(2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-5-yl)-4-quinazolinamine and N-(2,3-dihydro-1H-indol-5-yl)-4-quinazolinamine derivatives as perk inhibitors

Also Published As

Publication number Publication date
AR111281A1 (es) 2019-06-26
CO2019010078A2 (es) 2020-01-17
SG11201908517XA (en) 2019-10-30
CR20190433A (es) 2019-11-20
US20180265497A1 (en) 2018-09-20
EP3596063A1 (en) 2020-01-22
EP3596063A4 (en) 2020-12-30
CA3056833A1 (en) 2018-09-20
US10968203B2 (en) 2021-04-06
CL2019002671A1 (es) 2019-12-06
TW201838981A (zh) 2018-11-01
WO2018166528A1 (en) 2018-09-20
KR20190141145A (ko) 2019-12-23
JP6925435B2 (ja) 2021-08-25
IL269302A (en) 2019-11-28
BR112019019193A2 (pt) 2020-04-22
AU2018233402A1 (en) 2019-10-10
JP2020514377A (ja) 2020-05-21
CN111247136A (zh) 2020-06-05

Similar Documents

Publication Publication Date Title
PE20191557A1 (es) Compuestos de pirimidinil-pyridiloxi-naftil y metodos para tratar enfermedades y trastornos relacionados con ire1
PE20191541A1 (es) Composiciones y metodos para inhibir la accion de la arginasa
PE20200696A1 (es) Moduladores de moleculas pequenas de sting humana
MD3500564T2 (ro) Inhibitori ai diacilglicerol aciltransferazei 2
PE20210642A1 (es) Inhibidores de pd-1/pd-l1
CL2020002146A1 (es) Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer.
PE20151274A1 (es) Inhibidores de erk y sus usos
EA201991697A1 (ru) Сульфоксиминовые ингибиторы гликозидазы
PE20161438A1 (es) Inhibidores de desmetilasa 1 especifica a lisina
PE20171329A1 (es) Agentes inmunorreguladores
PE20161225A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
PE20170705A1 (es) Nuevos compuestos como inhibidores de ret (reorganizado durante la transfeccion)
PE20170695A1 (es) Compuestos de indol carboxamida utiles como inhibidores de cinasas
PE20141824A1 (es) Compuestos terapeuticamente activos y sus metodos de uso
EA201591743A1 (ru) СТИМУЛЯТОРЫ sGC
PE20160548A1 (es) Sulfonamidas como moduladores de canales de sodio
MX2017014584A (es) Inhibidores heterociclicos de erk1 y erk2 y su uso en el tratamiento del cancer.
PE20170004A1 (es) Inhibidores de biaril cinasa
PE20141855A1 (es) Benzotienilo-pirrolotriazinas disustituidas y sus usos
PE20140626A1 (es) Compuestos de bis(fluoroalquil)-1,4-benzodiazepinona
BR112015006828A8 (pt) composto, ou um sal farmaceuticamente aceitável do mesmo; composição farmacêutica; uso do composto; e método para modular a atividade de uma proteína ire1
AR085195A1 (es) Metodo de tratamiento de cancer
PE20170947A1 (es) 2-amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de bace1
PL417066A1 (pl) Inhibitory arginazy oraz ich zastosowania terapeutyczne
EA201500953A1 (ru) 3-ацетиламино-1-(фенилгетероариламинокарбонил или фенилгетероарилкарбониламино)бензольные производные для лечения гиперпролиферативных нарушений